ID   BLNK_MOUSE              Reviewed;         457 AA.
AC   Q9QUN3; O88504;
DT   22-NOV-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   07-APR-2021, entry version 156.
DE   RecName: Full=B-cell linker protein;
DE   AltName: Full=B-cell adapter containing a SH2 domain protein;
DE   AltName: Full=B-cell adapter containing a Src homology 2 domain protein;
DE   AltName: Full=Cytoplasmic adapter protein;
DE   AltName: Full=Lymphocyte antigen 57;
DE   AltName: Full=Src homology 2 domain-containing leukocyte protein of 65 kDa;
DE            Short=Slp-65;
GN   Name=Blnk; Synonyms=Bash, Ly57, Slp65;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=9697839; DOI=10.1016/s1074-7613(00)80591-9;
RA   Fu C., Turck C.W., Kurosaki T., Chan A.C.;
RT   "BLNK: a central linker protein in B cell activation.";
RL   Immunity 9:93-103(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], PROTEIN SEQUENCE OF 7-20; 147-161; 170-186;
RP   356-366 AND 393-412, FUNCTION, TISSUE SPECIFICITY, PHOSPHORYLATION, AND
RP   INTERACTION WITH VAV1 AND GRB2.
RC   STRAIN=BALB/cJ; TISSUE=Lymphoid tissue;
RX   PubMed=9705962; DOI=10.1084/jem.188.4.791;
RA   Wienands J., Schweikert J., Wollschied B., Jumaa H., Nielsen P.J., Reth M.;
RT   "SLP-65: a new signaling component in B lymphocytes which requires
RT   expression of the antigen receptor for phosphorylation.";
RL   J. Exp. Med. 188:791-795(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Okamoto N., Hayashi K., Tsuji S., Goitsuka R., Kitamura D.;
RT   "BASH: B lymphocyte adaptor protein containing SH2 domain.";
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Nielsen P.J., Guenet J.-L.;
RT   "The murine SLP-65 gene.";
RL   Submitted (NOV-2000) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=129; TISSUE=Mammary tumor;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   INTERACTION WITH CD79A, AND MUTAGENESIS OF ARG-373.
RX   PubMed=11449366;
RX   DOI=10.1002/1521-4141(200107)31:7<2126::aid-immu2126>3.0.co;2-o;
RA   Engels N., Wollscheid B., Wienands J.;
RT   "Association of SLP-65/BLNK with the B cell antigen receptor through a non-
RT   ITAM tyrosine of Ig-alpha.";
RL   Eur. J. Immunol. 31:2126-2134(2001).
RN   [7]
RP   INTERACTION WITH CD79A.
RX   PubMed=11859098; DOI=10.4049/jimmunol.168.5.2127;
RA   Siemasko K., Skaggs B.J., Kabak S., Williamson E., Brown B.K., Song W.,
RA   Clark M.R.;
RT   "Receptor-facilitated antigen presentation requires the recruitment of B
RT   cell linker protein to Igalpha.";
RL   J. Immunol. 168:2127-2138(2002).
RN   [8]
RP   INTERACTION WITH CD79A.
RX   PubMed=11909947; DOI=10.1128/mcb.22.8.2524-2535.2002;
RA   Kabak S., Skaggs B.J., Gold M.R., Affolter M., West K.L., Foster M.S.,
RA   Siemasko K., Chan A.C., Aebersold R., Clark M.R.;
RT   "The direct recruitment of BLNK to immunoglobulin alpha couples the B-cell
RT   antigen receptor to distal signaling pathways.";
RL   Mol. Cell. Biol. 22:2524-2535(2002).
RN   [9]
RP   FUNCTION IN PRO-B CELL TO PRE-B CELL TRANSITION, AND MUTAGENESIS OF TYR-52
RP   AND TYR-96.
RX   PubMed=12761551; DOI=10.1038/nature01608;
RA   Jumaa H., Bossaller L., Portugal K., Storch B., Lotz M., Flemming A.,
RA   Schrappe M., Postila V., Riikonen P., Pelkonen J., Niemeyer C.M., Reth M.;
RT   "Deficiency of the adaptor SLP-65 in pre-B-cell acute lymphoblastic
RT   leukaemia.";
RL   Nature 423:452-456(2003).
RN   [10]
RP   FUNCTION IN SYK ACTIVATION, INTERACTION WITH SYK, AND MUTAGENESIS OF
RP   ARG-373.
RX   PubMed=18369315; DOI=10.1038/emboj.2008.62;
RA   Kulathu Y., Hobeika E., Turchinovich G., Reth M.;
RT   "The kinase Syk as an adaptor controlling sustained calcium signalling and
RT   B-cell development.";
RL   EMBO J. 27:1333-1344(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [12]
RP   INTERACTION WITH SCIMP.
RX   PubMed=21930792; DOI=10.1128/mcb.05817-11;
RA   Draber P., Vonkova I., Stepanek O., Hrdinka M., Kucova M., Skopcova T.,
RA   Otahal P., Angelisova P., Horejsi V., Yeung M., Weiss A., Brdicka T.;
RT   "SCIMP, a transmembrane adapter protein involved in major
RT   histocompatibility complex class II signaling.";
RL   Mol. Cell. Biol. 31:4550-4562(2011).
RN   [13]
RP   INTERACTION WITH SCIMP.
RX   PubMed=28290451; DOI=10.1038/icb.2017.10;
RA   Luo L., Tong S.J., Wall A.A., Khromykh T., Sweet M.J., Stow J.L.;
RT   "Development of SH2 probes and pull-down assays to detect pathogen-induced,
RT   site-specific tyrosine phosphorylation of the TLR adaptor SCIMP.";
RL   Immunol. Cell Biol. 95:564-570(2017).
RN   [14]
RP   STRUCTURE BY NMR OF 328-457.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the SH2 domain from mouse B-cell linker protein
RT   BLNK.";
RL   Submitted (APR-2008) to the PDB data bank.
CC   -!- FUNCTION: Functions as a central linker protein, downstream of the B-
CC       cell receptor (BCR), bridging the SYK kinase to a multitude of
CC       signaling pathways and regulating biological outcomes of B-cell
CC       function and development. Plays a role in the activation of ERK/EPHB2,
CC       MAP kinase p38 and JNK. Modulates AP1 activation. Important for the
CC       activation of NF-kappa-B and NFAT. Plays an important role in BCR-
CC       mediated PLCG1 and PLCG2 activation and Ca(2+) mobilization and is
CC       required for trafficking of the BCR to late endosomes. However, does
CC       not seem to be required for pre-BCR-mediated activation of MAP kinase
CC       and phosphatidyl-inositol 3 (PI3) kinase signaling. May be required for
CC       the RAC1-JNK pathway. Plays a critical role in orchestrating the pro-B
CC       cell to pre-B cell transition. May play an important role in BCR-
CC       induced B-cell apoptosis. {ECO:0000269|PubMed:12761551,
CC       ECO:0000269|PubMed:18369315, ECO:0000269|PubMed:9705962}.
CC   -!- SUBUNIT: Associates with PLCG1, VAV1 and NCK1 in a B-cell antigen
CC       receptor-dependent fashion. Interacts with VAV3, PLCG2 and GRB2 (By
CC       similarity). Interacts through its SH2 domain with CD79A. Interacts
CC       (via SH2 domain) with SYK; phosphorylated and activated by SYK.
CC       Interacts (via SH2 domain) with SCIMP; this interaction is dependent on
CC       phosphorylation of SCIMP 'Tyr-120' (PubMed:21930792, PubMed:28290451).
CC       {ECO:0000250, ECO:0000269|PubMed:11449366, ECO:0000269|PubMed:11859098,
CC       ECO:0000269|PubMed:11909947, ECO:0000269|PubMed:18369315,
CC       ECO:0000269|PubMed:21930792, ECO:0000269|PubMed:28290451,
CC       ECO:0000269|PubMed:9705962}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Cell membrane
CC       {ECO:0000250}. Note=BCR activation results in the translocation to
CC       membrane fraction. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in the spleen and weakly in thymus, no
CC       expression was seen in liver, testis, or brain. Expressed in B-cell
CC       lines representing different developmental stages from the pre-B to the
CC       plasma cell stage, but not in a T-cell or a fibroblast cell line.
CC       {ECO:0000269|PubMed:9705962}.
CC   -!- PTM: Following BCR activation, phosphorylated on tyrosine residues by
CC       SYK and LYN. When phosphorylated, serves as a scaffold to assemble
CC       downstream targets of antigen activation, including PLCG1, VAV1, GRB2
CC       and NCK1. Phosphorylation of Tyr-84, Tyr-178 and Tyr-189 facilitates
CC       PLCG1 binding. Phosphorylation of Tyr-72 facilitates VAV1 and NCK1
CC       binding. Phosphorylation is required for both Ca(2+) and MAPK signaling
CC       pathways (By similarity). Phosphorylation of Tyr-96 is required for the
CC       binding of BTK. {ECO:0000250, ECO:0000269|PubMed:9705962}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF068182; AAC40206.1; -; mRNA.
DR   EMBL; Y17159; CAA76666.1; -; mRNA.
DR   EMBL; AB015290; BAA34944.1; -; mRNA.
DR   EMBL; AJ298054; CAC18565.1; -; Genomic_DNA.
DR   EMBL; BC059785; AAH59785.1; -; mRNA.
DR   CCDS; CCDS37983.1; -.
DR   RefSeq; NP_032554.2; NM_008528.4.
DR   PDB; 2EO6; NMR; -; A=330-457.
DR   PDBsum; 2EO6; -.
DR   SMR; Q9QUN3; -.
DR   BioGRID; 201236; 5.
DR   CORUM; Q9QUN3; -.
DR   IntAct; Q9QUN3; 7.
DR   MINT; Q9QUN3; -.
DR   STRING; 10090.ENSMUSP00000057844; -.
DR   iPTMnet; Q9QUN3; -.
DR   PhosphoSitePlus; Q9QUN3; -.
DR   MaxQB; Q9QUN3; -.
DR   PaxDb; Q9QUN3; -.
DR   PeptideAtlas; Q9QUN3; -.
DR   PRIDE; Q9QUN3; -.
DR   ProteomicsDB; 265305; -.
DR   Antibodypedia; 3990; 720 antibodies.
DR   Ensembl; ENSMUST00000054769; ENSMUSP00000057844; ENSMUSG00000061132.
DR   GeneID; 17060; -.
DR   KEGG; mmu:17060; -.
DR   UCSC; uc008hll.1; mouse.
DR   CTD; 29760; -.
DR   MGI; MGI:96878; Blnk.
DR   eggNOG; ENOG502QUXR; Eukaryota.
DR   GeneTree; ENSGT00940000155715; -.
DR   HOGENOM; CLU_043673_0_0_1; -.
DR   InParanoid; Q9QUN3; -.
DR   OMA; VHQKPIP; -.
DR   OrthoDB; 556782at2759; -.
DR   PhylomeDB; Q9QUN3; -.
DR   TreeFam; TF326567; -.
DR   Reactome; R-MMU-983695; Antigen activates B Cell Receptor (BCR) leading to generation of second messengers.
DR   BioGRID-ORCS; 17060; 1 hit in 52 CRISPR screens.
DR   ChiTaRS; Blnk; mouse.
DR   EvolutionaryTrace; Q9QUN3; -.
DR   PRO; PR:Q9QUN3; -.
DR   Proteomes; UP000000589; Chromosome 19.
DR   RNAct; Q9QUN3; protein.
DR   Bgee; ENSMUSG00000061132; Expressed in bone marrow and 173 other tissues.
DR   ExpressionAtlas; Q9QUN3; baseline and differential.
DR   Genevisible; Q9QUN3; MM.
DR   GO; GO:0005737; C:cytoplasm; IDA:MGI.
DR   GO; GO:0036464; C:cytoplasmic ribonucleoprotein granule; ISO:MGI.
DR   GO; GO:0005829; C:cytosol; ISO:MGI.
DR   GO; GO:0016020; C:membrane; ISO:MGI.
DR   GO; GO:0005886; C:plasma membrane; ISO:MGI.
DR   GO; GO:0019899; F:enzyme binding; ISO:MGI.
DR   GO; GO:1990782; F:protein tyrosine kinase binding; ISO:MGI.
DR   GO; GO:0042169; F:SH2 domain binding; ISO:MGI.
DR   GO; GO:0035591; F:signaling adaptor activity; ISO:MGI.
DR   GO; GO:0042113; P:B cell activation; IEA:UniProtKB-KW.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; ISO:MGI.
DR   GO; GO:0035556; P:intracellular signal transduction; ISO:MGI.
DR   GO; GO:0010628; P:positive regulation of gene expression; IMP:ARUK-UCL.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 3.30.505.10; -; 1.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   Pfam; PF00017; SH2; 1.
DR   SMART; SM00252; SH2; 1.
DR   SUPFAM; SSF55550; SSF55550; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; B-cell activation; Cell membrane; Cytoplasm;
KW   Direct protein sequencing; Membrane; Phosphoprotein; Reference proteome;
KW   SH2 domain.
FT   CHAIN           1..457
FT                   /note="B-cell linker protein"
FT                   /id="PRO_0000064941"
FT   DOMAIN          347..454
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   COMPBIAS        130..330
FT                   /note="Pro-rich"
FT   MOD_RES         72
FT                   /note="Phosphotyrosine; by SYK"
FT                   /evidence="ECO:0000250|UniProtKB:Q8WV28"
FT   MOD_RES         84
FT                   /note="Phosphotyrosine; by SYK"
FT                   /evidence="ECO:0000250|UniProtKB:Q8WV28"
FT   MOD_RES         96
FT                   /note="Phosphotyrosine; by SYK"
FT                   /evidence="ECO:0000250|UniProtKB:Q8WV28"
FT   MOD_RES         178
FT                   /note="Phosphotyrosine; by SYK"
FT                   /evidence="ECO:0000250|UniProtKB:Q8WV28"
FT   MOD_RES         189
FT                   /note="Phosphotyrosine; by SYK"
FT                   /evidence="ECO:0000250|UniProtKB:Q8WV28"
FT   MUTAGEN         52
FT                   /note="Y->F: No effect on pre-BCR down-regulation."
FT                   /evidence="ECO:0000269|PubMed:12761551"
FT   MUTAGEN         96
FT                   /note="Y->F: Fails to induce pre-BCR down-regulation,
FT                   leading to splenomegaly and leukemia."
FT                   /evidence="ECO:0000269|PubMed:12761551"
FT   MUTAGEN         373
FT                   /note="R->L: Abolishes binding to CD79A and SYK."
FT                   /evidence="ECO:0000269|PubMed:11449366,
FT                   ECO:0000269|PubMed:18369315"
FT   CONFLICT        333
FT                   /note="S -> L (in Ref. 1; AAC40206)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        340
FT                   /note="A -> G (in Ref. 1; AAC40206)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        356
FT                   /note="S -> F (in Ref. 1; AAC40206)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        376
FT                   /note="S -> F (in Ref. 1; AAC40206)"
FT                   /evidence="ECO:0000305"
FT   HELIX           334..340
FT                   /evidence="ECO:0007744|PDB:2EO6"
FT   TURN            341..344
FT                   /evidence="ECO:0007744|PDB:2EO6"
FT   STRAND          346..351
FT                   /evidence="ECO:0007744|PDB:2EO6"
FT   HELIX           354..364
FT                   /evidence="ECO:0007744|PDB:2EO6"
FT   STRAND          372..374
FT                   /evidence="ECO:0007744|PDB:2EO6"
FT   STRAND          383..390
FT                   /evidence="ECO:0007744|PDB:2EO6"
FT   STRAND          393..399
FT                   /evidence="ECO:0007744|PDB:2EO6"
FT   TURN            403..406
FT                   /evidence="ECO:0007744|PDB:2EO6"
FT   STRAND          410..412
FT                   /evidence="ECO:0007744|PDB:2EO6"
FT   STRAND          420..422
FT                   /evidence="ECO:0007744|PDB:2EO6"
FT   HELIX           423..432
FT                   /evidence="ECO:0007744|PDB:2EO6"
FT   STRAND          440..442
FT                   /evidence="ECO:0007744|PDB:2EO6"
SQ   SEQUENCE   457 AA;  50671 MW;  66C93D4FDDF9D260 CRC64;
     MDKLNKITVP ASQKLRQLQK MVHDIKNNEG GIMDKIKKLK VKGPPSVPRR DYALDSPADE
     EEQWSDDFDS DYENPDEHSD SEMYVMPAEE TGDDSYEPPP AEQQTRVVHP ALPFTRGEYV
     DNRSSQRHSP PFSKTLPSKP SWPSAKARLA STLPAPNSLQ KPQVPPKPKD LLEDEADYVV
     PVEDNDENYI HPRESSPPPA EKAPMVNRST KPNSSSKHMS PPGTVAGRNS GVWDSKSSLP
     AAPSPLPRAG KKPATPLKTT PVPPLPNASN VCEEKPVPAE RHRGSSHRQD TVQSPVFPPT
     QKPVHQKPVP LPRFPEAGSP AADGPFHSFP FNSTFADQEA ELLGKPWYAG ACDRKSAEEA
     LHRSNKDGSF LIRKSSGHDS KQPYTLVAFF NKRVYNIPVR FIEATKQYAL GKKKNGEEYF
     GSVVEIVNSH QHNPLVLIDS QNNTKDSTRL KYAVKVS
//
